World & BusinessImmunovant stock slides after reported halt to skin lupus drug program
Barron's reports that the biotech stopped developing its lead drug candidate, imeroprubart, for skin lupus following a trial miss.
TLDR
Barron's reports that Immunovant shares slid after the biotech halted development of its lead drug candidate, imeroprubart, for skin lupus following a trial miss.
Immunovant stock slides after reported halt to skin lupus drug program
Barron's reports that the biotech stopped developing its lead drug candidate, imeroprubart, for skin lupus following a trial miss.
TLDR
Barron's reports that Immunovant shares slid after the biotech halted development of its lead drug candidate, imeroprubart, for skin lupus following a trial miss.